Literature DB >> 24510743

Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesis.

Maurie Markman1.   

Abstract

The concept of "confirmatory" studies is a standard and important component of the overall clinical trials strategy in oncology. However, it is critical that such studies are similar enough in basic design and how they are conducted that they actually have the realistic potential to confirm, or refute, objectively the findings of the original study. In this commentary, two examples of clinical studies in the gynecologic oncology arena suggested by some to serve as "confirmatory" trials for the original reports demonstrate both the dangers and potential inappropriateness of such conclusions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510743     DOI: 10.1007/s11912-014-0381-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  7 in total

1.  Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

Authors:  Maurie Markman; John Blessing; Stephen C Rubin; Joseph Connor; Parviz Hanjani; Steven Waggoner
Journal:  Gynecol Oncol       Date:  2005-12-02       Impact factor: 5.482

2.  Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Authors:  Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Journal:  Gynecol Oncol       Date:  2009-05-17       Impact factor: 5.482

3.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

4.  Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

Authors:  Sergio Pecorelli; Giuseppe Favalli; Angiolo Gadducci; Dionyssios Katsaros; Pierluigi Benedetti Panici; Amalia Carpi; Giovanni Scambia; Michela Ballardini; Oriana Nanni; PierFranco Conte
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

5.  Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

Authors:  Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

6.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Seiji Isonishi; Fumiaki Takahashi; Hirofumi Michimae; Eizo Kimura; Daisuke Aoki; Toshiko Jobo; Shoji Kodama; Fumitoshi Terauchi; Toru Sugiyama; Kazunori Ochiai
Journal:  Lancet Oncol       Date:  2013-08-13       Impact factor: 41.316

7.  The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.

Authors:  Tsunekazu Kita; Yoshihiro Kikuchi; Masashi Takano; Mitsuaki Suzuki; Michitaka Oowada; Ryo Konno; Kenji Yamamoto; Hiromi Inoue; Hiroshi Seto; Tsutomu Yamamoto; Ken Shimizu
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.